[
  {
    "bcr_patient_uuid": "34C39A6B-DB6A-47E5-B0D4-5FA990EF7EB8",
    "patient_ID": "TCGA.3B.A9HI",
    "bcr_drug_barcode": "TCGA-3B-A9HI-D67109",
    "bcr_drug_uuid": "5EA39D1D-AA33-43F9-B8CF-2D2A7C2BDB12",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 850,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 959,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "34C39A6B-DB6A-47E5-B0D4-5FA990EF7EB8",
    "patient_ID": "TCGA.3B.A9HI",
    "bcr_drug_barcode": "TCGA-3B-A9HI-D68653",
    "bcr_drug_uuid": "18428FA9-5534-402D-A19C-0C4644083590",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 850,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 959,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "34C39A6B-DB6A-47E5-B0D4-5FA990EF7EB8",
    "patient_ID": "TCGA.3B.A9HI",
    "bcr_drug_barcode": "TCGA-3B-A9HI-D67110",
    "bcr_drug_uuid": "A972D93A-7742-4B10-B940-07B48E681B53",
    "form_completion_date": "2014-12-30",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 983,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1262,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "34C39A6B-DB6A-47E5-B0D4-5FA990EF7EB8",
    "patient_ID": "TCGA.3B.A9HI",
    "bcr_drug_barcode": "TCGA-3B-A9HI-D67111",
    "bcr_drug_uuid": "F6E1D28B-02E9-4B1C-9AE3-7B79F34DD15F",
    "form_completion_date": "2014-12-30",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 983,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1262,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "34C39A6B-DB6A-47E5-B0D4-5FA990EF7EB8",
    "patient_ID": "TCGA.3B.A9HI",
    "bcr_drug_barcode": "TCGA-3B-A9HI-D67112",
    "bcr_drug_uuid": "58214F70-0B9A-4DDB-92A5-512BFCA7ACCB",
    "form_completion_date": "2014-12-30",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1493,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AAF93A92-2F93-477D-9EA4-D18AB7D4F258",
    "patient_ID": "TCGA.3B.A9HL",
    "bcr_drug_barcode": "TCGA-3B-A9HL-D67361",
    "bcr_drug_uuid": "132BF65A-78F2-48DB-875C-986FB65F2D4D",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 185,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 215,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AAF93A92-2F93-477D-9EA4-D18AB7D4F258",
    "patient_ID": "TCGA.3B.A9HL",
    "bcr_drug_barcode": "TCGA-3B-A9HL-D67362",
    "bcr_drug_uuid": "89E1F63C-51CE-425E-8C84-95B55466B99B",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "DTIC, DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 447,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 481,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AAF93A92-2F93-477D-9EA4-D18AB7D4F258",
    "patient_ID": "TCGA.3B.A9HL",
    "bcr_drug_barcode": "TCGA-3B-A9HL-D67363",
    "bcr_drug_uuid": "7F868C4E-9F4C-4837-9827-528244347D9A",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 432,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AAF93A92-2F93-477D-9EA4-D18AB7D4F258",
    "patient_ID": "TCGA.3B.A9HL",
    "bcr_drug_barcode": "TCGA-3B-A9HL-D67364",
    "bcr_drug_uuid": "A08F4459-C37C-4652-A555-0E4BEA0B8E80",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 229,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 432,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "AAF93A92-2F93-477D-9EA4-D18AB7D4F258",
    "patient_ID": "TCGA.3B.A9HL",
    "bcr_drug_barcode": "TCGA-3B-A9HL-D67366",
    "bcr_drug_uuid": "060F3B2B-7107-4010-8D0F-AD1431115D91",
    "form_completion_date": "2014-11-4",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 532,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 542,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94615EA-551C-4F63-AF0D-5E49C87FC66E",
    "patient_ID": "TCGA.3B.A9HP",
    "bcr_drug_barcode": "TCGA-3B-A9HP-D68524",
    "bcr_drug_uuid": "B2360E51-9CED-4D6B-998F-C330E0B7C699",
    "form_completion_date": "2014-11-24",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 595,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 616,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F94615EA-551C-4F63-AF0D-5E49C87FC66E",
    "patient_ID": "TCGA.3B.A9HP",
    "bcr_drug_barcode": "TCGA-3B-A9HP-D68525",
    "bcr_drug_uuid": "7DC62343-856B-48C6-8D43-E4DA4463F70F",
    "form_completion_date": "2014-11-24",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 595,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 616,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68588",
    "bcr_drug_uuid": "8B225121-7684-4B38-9D82-432C2E43EB37",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1019,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1088,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68589",
    "bcr_drug_uuid": "A91B2C6B-CF7D-4CA1-86D0-7E4AF37FBEFE",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1019,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1088,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68590",
    "bcr_drug_uuid": "F77080D1-6AC0-42D0-9F01-678FA9F0306E",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "TRABECTEDIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1425,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1621,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68591",
    "bcr_drug_uuid": "613FA37B-F4F9-4FEA-867F-9E89B0AC3553",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1758,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2096,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68592",
    "bcr_drug_uuid": "6085945A-E678-4E14-B9D7-39D04A88BD8E",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2396,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68593",
    "bcr_drug_uuid": "5846808D-0289-44B8-B04B-C17210DC11E5",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2117,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2396,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "BFB21F9B-31AF-4ECC-A4F4-D7D3F5728E01",
    "patient_ID": "TCGA.3B.A9HR",
    "bcr_drug_barcode": "TCGA-3B-A9HR-D68594",
    "bcr_drug_uuid": "95942730-D152-44C2-B097-CEE4DF9E2EF1",
    "form_completion_date": "2014-12-1",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2396,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2683,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00EAAF62-C43E-4555-9134-1E5593386FDB",
    "patient_ID": "TCGA.3B.A9HS",
    "bcr_drug_barcode": "TCGA-3B-A9HS-D68599",
    "bcr_drug_uuid": "17776804-B5C0-426E-A7E2-96DBBC357392",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 568,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 592,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00EAAF62-C43E-4555-9134-1E5593386FDB",
    "patient_ID": "TCGA.3B.A9HS",
    "bcr_drug_barcode": "TCGA-3B-A9HS-D68600",
    "bcr_drug_uuid": "4FCD8A15-B0A2-46D7-AE09-AE0F19AFDBA4",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 568,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 592,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00EAAF62-C43E-4555-9134-1E5593386FDB",
    "patient_ID": "TCGA.3B.A9HS",
    "bcr_drug_barcode": "TCGA-3B-A9HS-D68601",
    "bcr_drug_uuid": "782C96B0-5406-4AFB-A630-D57ED5CF3032",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1034,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1132,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00EAAF62-C43E-4555-9134-1E5593386FDB",
    "patient_ID": "TCGA.3B.A9HS",
    "bcr_drug_barcode": "TCGA-3B-A9HS-D68602",
    "bcr_drug_uuid": "E008F582-9826-430B-95AE-AD2D5F0F8AD0",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1034,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1132,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "00EAAF62-C43E-4555-9134-1E5593386FDB",
    "patient_ID": "TCGA.3B.A9HS",
    "bcr_drug_barcode": "TCGA-3B-A9HS-D68603",
    "bcr_drug_uuid": "5B502ECA-BD85-4126-A513-6B20D74BF6D9",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "TEMOZOLOMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1202,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1243,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4B3C152F-A9EA-48CC-9189-F09078A92C48",
    "patient_ID": "TCGA.3B.A9HT",
    "bcr_drug_barcode": "TCGA-3B-A9HT-D68608",
    "bcr_drug_uuid": "A5DBA199-0F5F-4C30-978D-F25015901727",
    "form_completion_date": "2014-12-2",
    "pharmaceutical_therapy_drug_name": "CISPLATINUM",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 51,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 103,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "47FB776C-7839-4590-8F2D-6D149A0F1782",
    "patient_ID": "TCGA.3B.A9HV",
    "bcr_drug_barcode": "TCGA-3B-A9HV-D68629",
    "bcr_drug_uuid": "CDA1CE4D-C39A-4F5D-8553-1E87ED9488D6",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 271,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "47FB776C-7839-4590-8F2D-6D149A0F1782",
    "patient_ID": "TCGA.3B.A9HV",
    "bcr_drug_barcode": "TCGA-3B-A9HV-D68630",
    "bcr_drug_uuid": "A9FE99C8-F16A-41F6-8546-B8CB542E76C0",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 105,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 270,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "47FB776C-7839-4590-8F2D-6D149A0F1782",
    "patient_ID": "TCGA.3B.A9HV",
    "bcr_drug_barcode": "TCGA-3B-A9HV-D68631",
    "bcr_drug_uuid": "46337714-684D-436F-B191-3899FE559154",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 339,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 369,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "47FB776C-7839-4590-8F2D-6D149A0F1782",
    "patient_ID": "TCGA.3B.A9HV",
    "bcr_drug_barcode": "TCGA-3B-A9HV-D68632",
    "bcr_drug_uuid": "2419604F-4A3D-423A-A831-742368A39117",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 339,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 369,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32377DD2-C2A2-44FF-8938-B8CFB35DB79C",
    "patient_ID": "TCGA.3B.A9HZ",
    "bcr_drug_barcode": "TCGA-3B-A9HZ-D68638",
    "bcr_drug_uuid": "A79EDB17-F4A9-436A-B3B4-C554647096D6",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 482,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 602,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32377DD2-C2A2-44FF-8938-B8CFB35DB79C",
    "patient_ID": "TCGA.3B.A9HZ",
    "bcr_drug_barcode": "TCGA-3B-A9HZ-D68639",
    "bcr_drug_uuid": "A14D3AC9-B008-4365-93D7-A302C3672220",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 482,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 602,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32377DD2-C2A2-44FF-8938-B8CFB35DB79C",
    "patient_ID": "TCGA.3B.A9HZ",
    "bcr_drug_barcode": "TCGA-3B-A9HZ-D68640",
    "bcr_drug_uuid": "15EF1060-13E4-4D68-8319-D6682C4E38EE",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 834,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 889,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32377DD2-C2A2-44FF-8938-B8CFB35DB79C",
    "patient_ID": "TCGA.3B.A9HZ",
    "bcr_drug_barcode": "TCGA-3B-A9HZ-D68641",
    "bcr_drug_uuid": "92FF8EB2-7B91-433F-8258-95EC5D453D72",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 906,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1164,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32377DD2-C2A2-44FF-8938-B8CFB35DB79C",
    "patient_ID": "TCGA.3B.A9HZ",
    "bcr_drug_barcode": "TCGA-3B-A9HZ-D68642",
    "bcr_drug_uuid": "CC5F4D5A-1F73-44E1-9755-A50EEE407775",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 906,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1164,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A8CE2BE1-1F15-4E02-9161-5F161447A541",
    "patient_ID": "TCGA.3B.A9I0",
    "bcr_drug_barcode": "TCGA-3B-A9I0-D68644",
    "bcr_drug_uuid": "ECDD97E7-DEEB-4047-B6E7-FD9361AD4F27",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "clinical_trial_drug_classification": "CHEMOTHERAPY",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 580,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 706,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A8CE2BE1-1F15-4E02-9161-5F161447A541",
    "patient_ID": "TCGA.3B.A9I0",
    "bcr_drug_barcode": "TCGA-3B-A9I0-D68645",
    "bcr_drug_uuid": "9A810B8C-48D6-4181-AE50-23A947D5AEB9",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 948,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1054,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A8CE2BE1-1F15-4E02-9161-5F161447A541",
    "patient_ID": "TCGA.3B.A9I0",
    "bcr_drug_barcode": "TCGA-3B-A9I0-D68646",
    "bcr_drug_uuid": "0087FFBB-A1B6-4358-B3A3-C2A478E6B4E3",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 941,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1054,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A4F68239-5B9F-40D7-9E52-B68EFA170C1C",
    "patient_ID": "TCGA.3B.A9I1",
    "bcr_drug_barcode": "TCGA-3B-A9I1-D68648",
    "bcr_drug_uuid": "65534F66-EAAA-41FE-A647-968C23245532",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 71,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 176,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A4F68239-5B9F-40D7-9E52-B68EFA170C1C",
    "patient_ID": "TCGA.3B.A9I1",
    "bcr_drug_barcode": "TCGA-3B-A9I1-D68649",
    "bcr_drug_uuid": "5D917405-3B35-4BCA-A9F5-34FA0012BA45",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 36,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 36,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A4F68239-5B9F-40D7-9E52-B68EFA170C1C",
    "patient_ID": "TCGA.3B.A9I1",
    "bcr_drug_barcode": "TCGA-3B-A9I1-D68650",
    "bcr_drug_uuid": "BEDE14A8-2C61-454C-8B93-237A0FD97CB7",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 332,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 388,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A4F68239-5B9F-40D7-9E52-B68EFA170C1C",
    "patient_ID": "TCGA.3B.A9I1",
    "bcr_drug_barcode": "TCGA-3B-A9I1-D68651",
    "bcr_drug_uuid": "9B7ADE90-93B3-4A9F-B507-7D655D8B410B",
    "form_completion_date": "2014-12-5",
    "pharmaceutical_therapy_drug_name": "FEMARA",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 437,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 500,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E786DE34-4C21-460F-89AB-008DE4347049",
    "patient_ID": "TCGA.DX.A3LU",
    "bcr_drug_barcode": "TCGA-DX-A3LU-D65076",
    "bcr_drug_uuid": "EBF0585E-7F9B-4A38-81C3-CE360EE3E706",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 451,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 492,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E786DE34-4C21-460F-89AB-008DE4347049",
    "patient_ID": "TCGA.DX.A3LU",
    "bcr_drug_barcode": "TCGA-DX-A3LU-D65077",
    "bcr_drug_uuid": "8E48013C-3685-4DA0-B409-181AAD2E9E94",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 451,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 492,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E786DE34-4C21-460F-89AB-008DE4347049",
    "patient_ID": "TCGA.DX.A3LU",
    "bcr_drug_barcode": "TCGA-DX-A3LU-D65078",
    "bcr_drug_uuid": "5706FF0E-9B87-4608-A068-3DB37D357DED",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "PD 0332991",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1974,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2200,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "6201394F-B70E-4F14-9519-FF9D5F06EB09",
    "patient_ID": "TCGA.DX.A3U6",
    "bcr_drug_barcode": "TCGA-DX-A3U6-D65073",
    "bcr_drug_uuid": "C84039E6-6BD8-4D3B-9513-2CE0D13EA507",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "PD 0332991",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 484,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 540,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "6201394F-B70E-4F14-9519-FF9D5F06EB09",
    "patient_ID": "TCGA.DX.A3U6",
    "bcr_drug_barcode": "TCGA-DX-A3U6-D65075",
    "bcr_drug_uuid": "189AE7BF-E279-41C5-8F1E-2D9996AEDF8B",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 554,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 966,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65085",
    "bcr_drug_uuid": "594DDFF8-FF53-49A8-9128-6A36B86F3D05",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 350,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 549,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65086",
    "bcr_drug_uuid": "F8E35288-0F88-4B05-9AD0-7D3675A89384",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 350,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 606,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65087",
    "bcr_drug_uuid": "845AB61D-39D8-41B0-9683-6B99A9DA8928",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 741,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 922,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65088",
    "bcr_drug_uuid": "E91F4B1E-FA07-42EA-AE25-F8CB3540CD14",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 741,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 922,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65089",
    "bcr_drug_uuid": "E94F344D-5843-4A36-BE02-2C0F48B1FAB9",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 942,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 945,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65090",
    "bcr_drug_uuid": "7D66E221-BFA1-43A3-A68F-93BF12D7D4E9",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 969,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1126,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65092",
    "bcr_drug_uuid": "8708AEE3-C54B-4CF4-B059-2C68BB6DBB32",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1182,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65093",
    "bcr_drug_uuid": "B93EA1CC-B0AE-47E1-86B7-C6B65907D6CB",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1258,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1301,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EA3A524B-6EE3-4904-8924-29FCAA20985C",
    "patient_ID": "TCGA.DX.A3U7",
    "bcr_drug_barcode": "TCGA-DX-A3U7-D65094",
    "bcr_drug_uuid": "00BC2544-855A-4E58-89E4-F5DC86A187CF",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1352,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1427,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65139",
    "bcr_drug_uuid": "EEFE83A8-CE01-44A8-BE8B-BB946B538F69",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 629,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 709,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65141",
    "bcr_drug_uuid": "CEE8BF98-3310-4B1C-A3F8-1DCF61FFEB7F",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1045,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1119,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65143",
    "bcr_drug_uuid": "D9231AE2-F09C-490A-BF8B-E95910B19D8A",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1045,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1119,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65144",
    "bcr_drug_uuid": "6E763C09-F1EA-47F1-AC41-C3CCEB635CD5",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1144,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1287,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65145",
    "bcr_drug_uuid": "23DFB046-1F7A-4A6F-856E-FEE658C59F0E",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "ET-743",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1308,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1329,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "778DC00A-0B94-45A8-AE13-9C80F0C1DFD6",
    "patient_ID": "TCGA.DX.A3UC",
    "bcr_drug_barcode": "TCGA-DX-A3UC-D65146",
    "bcr_drug_uuid": "CBFB8972-2494-4A04-843B-27837D311A80",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1675,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1675,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5B9D27A3-7483-4118-A719-A164800BA957",
    "patient_ID": "TCGA.DX.A3UF",
    "bcr_drug_barcode": "TCGA-DX-A3UF-D65079",
    "bcr_drug_uuid": "DA257D5C-140C-4E8F-8D06-FA4FE2851494",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "MORAB-004",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1802,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1915,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "5B9D27A3-7483-4118-A719-A164800BA957",
    "patient_ID": "TCGA.DX.A3UF",
    "bcr_drug_barcode": "TCGA-DX-A3UF-D65080",
    "bcr_drug_uuid": "C89291BE-0C79-49EE-90BD-1853AC6FDD72",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "MLN8237",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1938,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1945,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0AC700F3-C9CF-4ED7-A8BD-975527750024",
    "patient_ID": "TCGA.DX.A6B7",
    "bcr_drug_barcode": "TCGA-DX-A6B7-D45497",
    "bcr_drug_uuid": "76209A84-5125-4EB7-9FCD-6B759DFB0B07",
    "form_completion_date": "2014-9-16",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 86,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0AC700F3-C9CF-4ED7-A8BD-975527750024",
    "patient_ID": "TCGA.DX.A6B7",
    "bcr_drug_barcode": "TCGA-DX-A6B7-D45499",
    "bcr_drug_uuid": "9329C693-E4D4-4C52-AE1B-18130585B441",
    "form_completion_date": "2014-9-16",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 65,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 72,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9C58E3B2-1DEE-4375-8239-CE69A725E3DE",
    "patient_ID": "TCGA.DX.A6B8",
    "bcr_drug_barcode": "TCGA-DX-A6B8-D45502",
    "bcr_drug_uuid": "B58C7E85-E693-47DB-BDA6-54C936C6B22D",
    "form_completion_date": "2014-9-16",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 255,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4DC28966-D2C4-4661-B71F-D7F85E536CB6",
    "patient_ID": "TCGA.DX.A6BA",
    "bcr_drug_barcode": "TCGA-DX-A6BA-D60712",
    "bcr_drug_uuid": "3D5CA7E5-57BC-4E74-AC20-BF3B9A8FAC60",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1493,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4DC28966-D2C4-4661-B71F-D7F85E536CB6",
    "patient_ID": "TCGA.DX.A6BA",
    "bcr_drug_barcode": "TCGA-DX-A6BA-D60713",
    "bcr_drug_uuid": "80BC3AAB-C064-4589-8F0E-D37922976D8E",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 705,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 867,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4DC28966-D2C4-4661-B71F-D7F85E536CB6",
    "patient_ID": "TCGA.DX.A6BA",
    "bcr_drug_barcode": "TCGA-DX-A6BA-D60714",
    "bcr_drug_uuid": "9B253B9D-07A1-417B-9CBC-9A56094CBDE6",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 525,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 567,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "4DC28966-D2C4-4661-B71F-D7F85E536CB6",
    "patient_ID": "TCGA.DX.A6BA",
    "bcr_drug_barcode": "TCGA-DX-A6BA-D60715",
    "bcr_drug_uuid": "012BE891-8C9B-42DF-B8D9-7F0E56FE094E",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "R1507",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 525,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 567,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "4DC28966-D2C4-4661-B71F-D7F85E536CB6",
    "patient_ID": "TCGA.DX.A6BA",
    "bcr_drug_barcode": "TCGA-DX-A6BA-D60716",
    "bcr_drug_uuid": "802F88B9-C0F9-4616-B853-9347766A050B",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 446,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 507,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "969954A8-7F15-4052-9E6A-C5956115F3AD",
    "patient_ID": "TCGA.DX.A6BG",
    "bcr_drug_barcode": "TCGA-DX-A6BG-D45616",
    "bcr_drug_uuid": "A0EB27B5-C1AF-4852-84AC-1E484BD74EE1",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "PD 0332991",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 161,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 191,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "969954A8-7F15-4052-9E6A-C5956115F3AD",
    "patient_ID": "TCGA.DX.A6BG",
    "bcr_drug_barcode": "TCGA-DX-A6BG-D45617",
    "bcr_drug_uuid": "CA150DA7-9A7A-4650-B336-3C3612858664",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 198,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "969954A8-7F15-4052-9E6A-C5956115F3AD",
    "patient_ID": "TCGA.DX.A6BG",
    "bcr_drug_barcode": "TCGA-DX-A6BG-D45618",
    "bcr_drug_uuid": "F543A8BE-1A74-4096-BA30-9C49D688D5C9",
    "form_completion_date": "2013-7-17",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 198,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ECC74D54-D929-4DD0-B9EC-E03163343F9A",
    "patient_ID": "TCGA.DX.A6YX",
    "bcr_drug_barcode": "TCGA-DX-A6YX-D64694",
    "bcr_drug_uuid": "F8BBDC77-3BC9-4EB0-843C-E91E4209B203",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 285,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 407,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ECC74D54-D929-4DD0-B9EC-E03163343F9A",
    "patient_ID": "TCGA.DX.A6YX",
    "bcr_drug_barcode": "TCGA-DX-A6YX-D64697",
    "bcr_drug_uuid": "BAF5ECD2-3691-45DB-950E-F697DEFA0E0B",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 292,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 407,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "ECC74D54-D929-4DD0-B9EC-E03163343F9A",
    "patient_ID": "TCGA.DX.A6YX",
    "bcr_drug_barcode": "TCGA-DX-A6YX-D64698",
    "bcr_drug_uuid": "395A4BE2-93F9-45A9-841E-6BC6BF7515E7",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "LIPOSOMAL DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 444,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 484,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2C9F737B-0D37-4931-AFF5-4562A0057BAE",
    "patient_ID": "TCGA.DX.A7EI",
    "bcr_drug_barcode": "TCGA-DX-A7EI-D60717",
    "bcr_drug_uuid": "D09C4F0C-50D1-432B-A584-8A29CA848989",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 990,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 991,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3ED1862B-C6EF-4744-9123-BB1EE557F068",
    "patient_ID": "TCGA.DX.A7EN",
    "bcr_drug_barcode": "TCGA-DX-A7EN-D60718",
    "bcr_drug_uuid": "58699DE8-D593-4D9E-81EA-A36D28AE3162",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "PAZOPANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 352,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3ED1862B-C6EF-4744-9123-BB1EE557F068",
    "patient_ID": "TCGA.DX.A7EN",
    "bcr_drug_barcode": "TCGA-DX-A7EN-D60720",
    "bcr_drug_uuid": "80C2A2F2-EFDD-4E75-93BA-A245A18DC96D",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3ED1862B-C6EF-4744-9123-BB1EE557F068",
    "patient_ID": "TCGA.DX.A7EN",
    "bcr_drug_barcode": "TCGA-DX-A7EN-D60721",
    "bcr_drug_uuid": "0BD1DF00-FC15-4194-8214-AC5D214EA20E",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 34,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60696",
    "bcr_drug_uuid": "D27CB166-13CA-460C-8CA3-FB794E41FB16",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "VORINOSTAT",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 791,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 830,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60697",
    "bcr_drug_uuid": "4F185FCC-D9B9-41DC-971D-38A1463EF528",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 675,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60698",
    "bcr_drug_uuid": "D1842C93-E9EC-4C31-9FF9-4DEF0D902B28",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 559,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 675,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60699",
    "bcr_drug_uuid": "BCDEC186-03C6-40B6-86B3-72B14D481767",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 451,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 508,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60700",
    "bcr_drug_uuid": "1EEFA959-7108-4272-88F7-A8E284234A7D",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 403,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 424,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0B6418FC-C775-4BAA-8776-74FFCC492E9A",
    "patient_ID": "TCGA.DX.A7EQ",
    "bcr_drug_barcode": "TCGA-DX-A7EQ-D60701",
    "bcr_drug_uuid": "915DE7E1-221A-4819-B8B2-B86DEC0356FC",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 293,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 349,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "505DC15C-4F74-43DE-8EAF-32B7D7515EDB",
    "patient_ID": "TCGA.DX.A8BH",
    "bcr_drug_barcode": "TCGA-DX-A8BH-D65072",
    "bcr_drug_uuid": "FF83EB98-8ECA-41EB-A5D1-BD90B124131F",
    "form_completion_date": "2014-9-18",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 280,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EEA7D707-AEB9-4D00-AB5E-C1EA608517E9",
    "patient_ID": "TCGA.DX.A8BT",
    "bcr_drug_barcode": "TCGA-DX-A8BT-D70335",
    "bcr_drug_uuid": "3A9369AD-BAC5-40FB-A347-516D0D22F29C",
    "form_completion_date": "2015-2-5",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 697,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 773,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "EEA7D707-AEB9-4D00-AB5E-C1EA608517E9",
    "patient_ID": "TCGA.DX.A8BT",
    "bcr_drug_barcode": "TCGA-DX-A8BT-D70336",
    "bcr_drug_uuid": "C99620DF-64EF-47AE-9C97-4D5477E2387E",
    "form_completion_date": "2015-2-5",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 697,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 773,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60702",
    "bcr_drug_uuid": "65C5ED45-BA64-48E3-A23E-479F1815C93E",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1080,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1081,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60703",
    "bcr_drug_uuid": "0D8DD5C7-8632-4273-9D7F-6D877CDC6C4C",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 678,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1035,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60704",
    "bcr_drug_uuid": "F5154121-D71B-449A-A174-9AD136B351C8",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 678,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1035,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60705",
    "bcr_drug_uuid": "795DFCAD-BA50-4624-AABE-25649A5DA2CD",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 590,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 647,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60706",
    "bcr_drug_uuid": "7A9B6B27-AF3F-4EF6-9340-642035408FD4",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4996E458-DB04-4C6D-9AE6-66316240A8ED",
    "patient_ID": "TCGA.DX.A8BU",
    "bcr_drug_barcode": "TCGA-DX-A8BU-D60707",
    "bcr_drug_uuid": "D9969726-D45C-43B9-8CBD-A01BD43A7474",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 123,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 228,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "07A6BBCE-012B-48FE-8C62-E79A1B200EB6",
    "patient_ID": "TCGA.DX.A8BV",
    "bcr_drug_barcode": "TCGA-DX-A8BV-D60708",
    "bcr_drug_uuid": "BD318FB3-80E6-4636-BBB6-A162FA5B0E7F",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 750,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 903,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "07A6BBCE-012B-48FE-8C62-E79A1B200EB6",
    "patient_ID": "TCGA.DX.A8BV",
    "bcr_drug_barcode": "TCGA-DX-A8BV-D60709",
    "bcr_drug_uuid": "EEB9D58C-71C5-4612-B9DD-8B52E06B89D1",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 750,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 903,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "07A6BBCE-012B-48FE-8C62-E79A1B200EB6",
    "patient_ID": "TCGA.DX.A8BV",
    "bcr_drug_barcode": "TCGA-DX-A8BV-D60710",
    "bcr_drug_uuid": "AEF5DDBE-A922-418A-A316-F80A3F1DFF62",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 415,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 446,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "07A6BBCE-012B-48FE-8C62-E79A1B200EB6",
    "patient_ID": "TCGA.DX.A8BV",
    "bcr_drug_barcode": "TCGA-DX-A8BV-D60711",
    "bcr_drug_uuid": "CD219A80-1126-4EB9-965A-23318CDB8DDF",
    "form_completion_date": "2014-6-13",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 415,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 446,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CC9EB46B-47A6-44B2-97C1-3EE866BBFC3D",
    "patient_ID": "TCGA.DX.AB2E",
    "bcr_drug_barcode": "TCGA-DX-AB2E-D68335",
    "bcr_drug_uuid": "A9807230-AA1E-4ABB-95D7-02DB246D4919",
    "form_completion_date": "2014-11-14",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CC9EB46B-47A6-44B2-97C1-3EE866BBFC3D",
    "patient_ID": "TCGA.DX.AB2E",
    "bcr_drug_barcode": "TCGA-DX-AB2E-D68336",
    "bcr_drug_uuid": "75B14BCA-1B14-4F1D-B3C7-1FE089E7130A",
    "form_completion_date": "2014-11-14",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 133,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 222,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CC9EB46B-47A6-44B2-97C1-3EE866BBFC3D",
    "patient_ID": "TCGA.DX.AB2E",
    "bcr_drug_barcode": "TCGA-DX-AB2E-D68337",
    "bcr_drug_uuid": "258EE710-6AA1-4B96-A26D-FC1FA29DECB8",
    "form_completion_date": "2014-11-14",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 253,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "91F6EB4C-0143-47B9-BCBD-5332D913A039",
    "patient_ID": "TCGA.DX.AB3B",
    "bcr_drug_barcode": "TCGA-DX-AB3B-D64994",
    "bcr_drug_uuid": "D9361777-D032-42C0-8C40-ADC628EDDF2B",
    "form_completion_date": "2014-9-17",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 158,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "91F6EB4C-0143-47B9-BCBD-5332D913A039",
    "patient_ID": "TCGA.DX.AB3B",
    "bcr_drug_barcode": "TCGA-DX-AB3B-D64995",
    "bcr_drug_uuid": "21B1FE2A-BDE4-4BDE-94BC-8092D9E422E2",
    "form_completion_date": "2014-9-17",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 158,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "94359EDF-7208-4B4C-AD7C-4064974DE818",
    "patient_ID": "TCGA.DX.AB3C",
    "bcr_drug_barcode": "TCGA-DX-AB3C-D64710",
    "bcr_drug_uuid": "697FCF21-D87F-4975-AFD9-99FE8CB1E0BD",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 48,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "94359EDF-7208-4B4C-AD7C-4064974DE818",
    "patient_ID": "TCGA.DX.AB3C",
    "bcr_drug_barcode": "TCGA-DX-AB3C-D64711",
    "bcr_drug_uuid": "6709787C-A6E0-43F4-8EA6-9891DB23CC58",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "ETOPOSIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 90,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 181,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "94359EDF-7208-4B4C-AD7C-4064974DE818",
    "patient_ID": "TCGA.DX.AB3C",
    "bcr_drug_barcode": "TCGA-DX-AB3C-D64712",
    "bcr_drug_uuid": "08402FF2-FD58-4EA4-8686-6A93A227C7D4",
    "form_completion_date": "2014-9-9",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 48,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 89,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "7F9031DA-124A-4A38-83E6-878A50E58C24",
    "patient_ID": "TCGA.FX.A3RE",
    "bcr_drug_barcode": "TCGA-FX-A3RE-D66009",
    "bcr_drug_uuid": "E6423623-8D9D-4F05-82E7-F87E9F26EDA4",
    "form_completion_date": "2014-10-1",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 63,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 136,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12BFD446-2EE5-4664-A492-C023D134F60F",
    "patient_ID": "TCGA.FX.A48G",
    "bcr_drug_barcode": "TCGA-FX-A48G-D64193",
    "bcr_drug_uuid": "F655E223-1B79-448A-BC37-D531A839463E",
    "form_completion_date": "2014-8-27",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12BFD446-2EE5-4664-A492-C023D134F60F",
    "patient_ID": "TCGA.FX.A48G",
    "bcr_drug_barcode": "TCGA-FX-A48G-D64194",
    "bcr_drug_uuid": "C79952AA-F29F-4FD7-B8CD-F639490F23D2",
    "form_completion_date": "2014-8-27",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 54,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 168,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12BFD446-2EE5-4664-A492-C023D134F60F",
    "patient_ID": "TCGA.FX.A48G",
    "bcr_drug_barcode": "TCGA-FX-A48G-D64196",
    "bcr_drug_uuid": "EAF176DE-3FC3-4598-9674-2384C283A943",
    "form_completion_date": "2014-8-27",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 174,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 289,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12BFD446-2EE5-4664-A492-C023D134F60F",
    "patient_ID": "TCGA.FX.A48G",
    "bcr_drug_barcode": "TCGA-FX-A48G-D64197",
    "bcr_drug_uuid": "79DC51AA-ADA8-4E0D-9B1C-FAB2A9B5901E",
    "form_completion_date": "2014-8-27",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 309,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 414,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "12BFD446-2EE5-4664-A492-C023D134F60F",
    "patient_ID": "TCGA.FX.A48G",
    "bcr_drug_barcode": "TCGA-FX-A48G-D64198",
    "bcr_drug_uuid": "FD5F07E2-247C-44F7-9E91-14AFDD2E30E7",
    "form_completion_date": "2014-8-27",
    "pharmaceutical_therapy_drug_name": "CARBOPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 503,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 593,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "30CADE9C-A0E0-4BE6-9DAB-1C495630FD1A",
    "patient_ID": "TCGA.FX.A8OO",
    "bcr_drug_barcode": "TCGA-FX-A8OO-D72528",
    "bcr_drug_uuid": "530C1BE6-14C5-401F-9247-EBE4171AC3B9",
    "form_completion_date": "2015-7-10",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 118,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 243,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "520088B0-FFC0-4ECD-B1ED-2339811D7AD2",
    "patient_ID": "TCGA.HB.A3L4",
    "bcr_drug_barcode": "TCGA-HB-A3L4-D31059",
    "bcr_drug_uuid": "CD4E5077-1710-45DF-A2B0-EBA935547265",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 431,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 473,
    "drug_cycles": 3,
    "drug_units": "MG/M2",
    "drug_dose": 50,
    "regimen_number": 2,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "520088B0-FFC0-4ECD-B1ED-2339811D7AD2",
    "patient_ID": "TCGA.HB.A3L4",
    "bcr_drug_barcode": "TCGA-HB-A3L4-D31063",
    "bcr_drug_uuid": "4E074E7D-F1A8-44B8-BE6C-89DEAB54EB9A",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 734,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 945,
    "drug_cycles": 11,
    "drug_units": "G/DAY",
    "drug_dose": 2.8,
    "regimen_number": 4,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "520088B0-FFC0-4ECD-B1ED-2339811D7AD2",
    "patient_ID": "TCGA.HB.A3L4",
    "bcr_drug_barcode": "TCGA-HB-A3L4-D31054",
    "bcr_drug_uuid": "A15FF76E-CC7F-4516-87DD-DF991F117224",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_cycles": 8,
    "drug_units": "MG/M2",
    "drug_dose": 100,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "520088B0-FFC0-4ECD-B1ED-2339811D7AD2",
    "patient_ID": "TCGA.HB.A3L4",
    "bcr_drug_barcode": "TCGA-HB-A3L4-D31061",
    "bcr_drug_uuid": "0E5F55B3-453A-4385-A678-A2457422C74D",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "LETROZOLE",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 582,
    "pharmaceutical_tx_ongoing_indicator": true,
    "drug_units": "MG/DAY",
    "drug_dose": 2.5,
    "regimen_number": 3,
    "drug_route": "ORAL",
    "therapy_regimen": "PROGRESSION"
  },
  {
    "bcr_patient_uuid": "520088B0-FFC0-4ECD-B1ED-2339811D7AD2",
    "patient_ID": "TCGA.HB.A3L4",
    "bcr_drug_barcode": "TCGA-HB-A3L4-D31053",
    "bcr_drug_uuid": "4726B8D2-7F3D-479B-BAC7-2BE2AAA6292A",
    "form_completion_date": "2012-4-23",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 32,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 216,
    "drug_cycles": 8,
    "drug_units": "MG/M2",
    "drug_dose": 900,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT"
  },
  {
    "bcr_patient_uuid": "9C9B53E5-CDBE-4510-A839-4A3B5039681B",
    "patient_ID": "TCGA.HB.A43Z",
    "bcr_drug_barcode": "TCGA-HB-A43Z-D50689",
    "bcr_drug_uuid": "5F09268D-2947-4627-8C4A-FA104BF5676A",
    "form_completion_date": "2013-10-29",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 105,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9C9B53E5-CDBE-4510-A839-4A3B5039681B",
    "patient_ID": "TCGA.HB.A43Z",
    "bcr_drug_barcode": "TCGA-HB-A43Z-D50690",
    "bcr_drug_uuid": "2D31D09A-B7C4-4656-A447-2E9140CE27E1",
    "form_completion_date": "2013-10-29",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 105,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9C9B53E5-CDBE-4510-A839-4A3B5039681B",
    "patient_ID": "TCGA.HB.A43Z",
    "bcr_drug_barcode": "TCGA-HB-A43Z-D50691",
    "bcr_drug_uuid": "D483DCCF-3CAE-40DA-AE10-5B0960B9102C",
    "form_completion_date": "2013-10-29",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 126,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 189,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2948D657-E5DD-4D6E-91B5-88C54F73AC31",
    "patient_ID": "TCGA.HS.A5N9",
    "bcr_drug_barcode": "TCGA-HS-A5N9-D49073",
    "bcr_drug_uuid": "28495FFD-1C69-4764-B8CD-EECB58F90DF0",
    "form_completion_date": "2013-9-25",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 42,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 91,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "2948D657-E5DD-4D6E-91B5-88C54F73AC31",
    "patient_ID": "TCGA.HS.A5N9",
    "bcr_drug_barcode": "TCGA-HS-A5N9-D49078",
    "bcr_drug_uuid": "756B43EB-8191-484B-92CE-2D8F9A608158",
    "form_completion_date": "2013-9-25",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 49,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 91,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42510",
    "bcr_drug_uuid": "7E52B038-4CA0-4A8A-8A2C-C2771F77E17E",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE (DTIC)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 102,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42511",
    "bcr_drug_uuid": "92A8EA72-1FDD-4D84-B249-FE68509796E0",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 102,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42512",
    "bcr_drug_uuid": "D1F8C9CD-9448-4807-9262-4E14B008910F",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 778,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 836,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42513",
    "bcr_drug_uuid": "7197956D-15AF-4DF6-9E4C-309575A10959",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 787,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 836,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42514",
    "bcr_drug_uuid": "29E2D3B7-FCE4-4800-A064-395E7B1CD3B4",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "ET-743",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1411,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1594,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42515",
    "bcr_drug_uuid": "6FF6DD1F-AC2A-414D-AA89-746B8F5872C7",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "AP-23573 (ARIAD)",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 1609,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1660,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42516",
    "bcr_drug_uuid": "B7432680-8022-4606-9337-709B9E42F436",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "EZN-2968",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 1834,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1918,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42517",
    "bcr_drug_uuid": "42E7D909-7056-4AB8-AF20-A37A812A4554",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "ENOTICUMAB",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 1973,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2037,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42518",
    "bcr_drug_uuid": "E347A30F-D343-4DCF-BCC4-3A650F6F36B0",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "THRESHOLD-302",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2073,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2093,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "24D08A93-D078-407B-8D93-5F7A099821EB",
    "patient_ID": "TCGA.IE.A3OV",
    "bcr_drug_barcode": "TCGA-IE-A3OV-D42519",
    "bcr_drug_uuid": "A3AA7DBF-C64A-42F1-ABFC-CFBDFAC513A6",
    "form_completion_date": "2013-4-23",
    "pharmaceutical_therapy_drug_name": "ALIMTA",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2232,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2293,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "32344F23-524B-4182-AE75-6AD6128EEBA0",
    "patient_ID": "TCGA.IE.A4EH",
    "bcr_drug_barcode": "TCGA-IE-A4EH-D41932",
    "bcr_drug_uuid": "42163DDA-EA18-4EC7-A948-F04CCB6E19B7",
    "form_completion_date": "2013-4-4",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 326,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 448,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "32344F23-524B-4182-AE75-6AD6128EEBA0",
    "patient_ID": "TCGA.IE.A4EH",
    "bcr_drug_barcode": "TCGA-IE-A4EH-D41004",
    "bcr_drug_uuid": "2AE43EDC-BF5E-44E9-9A34-E51048BEE543",
    "form_completion_date": "2013-4-4",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 326,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 448,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "885B1B65-4280-4AAB-A7F0-434B0317D86F",
    "patient_ID": "TCGA.IE.A6BZ",
    "bcr_drug_barcode": "TCGA-IE-A6BZ-D52320",
    "bcr_drug_uuid": "A3BB1EE7-CCE3-4913-9CC9-3590EBE9A40B",
    "form_completion_date": "2013-12-2",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 204,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "885B1B65-4280-4AAB-A7F0-434B0317D86F",
    "patient_ID": "TCGA.IE.A6BZ",
    "bcr_drug_barcode": "TCGA-IE-A6BZ-D52322",
    "bcr_drug_uuid": "594A5B72-62E0-4BDB-8174-F789A03B36E6",
    "form_completion_date": "2013-12-2",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 204,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "885B1B65-4280-4AAB-A7F0-434B0317D86F",
    "patient_ID": "TCGA.IE.A6BZ",
    "bcr_drug_barcode": "TCGA-IE-A6BZ-D52329",
    "bcr_drug_uuid": "D1351D43-3BBC-4C74-AE1B-B75DF32F8D1E",
    "form_completion_date": "2013-12-2",
    "pharmaceutical_therapy_drug_name": "MESNA",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 112,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 204,
    "treatment_best_response": "COMPLETE RESPONSE"
  },
  {
    "bcr_patient_uuid": "8488BB97-BF11-45CC-B1BD-52969598448D",
    "patient_ID": "TCGA.IF.A3RQ",
    "bcr_drug_barcode": "TCGA-IF-A3RQ-D41984",
    "bcr_drug_uuid": "FC8C64CF-DFB9-4A7C-AFEB-8F1ACF6CD564",
    "form_completion_date": "2013-4-8",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 441,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 457,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4E8C570C-3CBE-4878-8B2C-B966868DD60D",
    "patient_ID": "TCGA.IF.A4AJ",
    "bcr_drug_barcode": "TCGA-IF-A4AJ-D41987",
    "bcr_drug_uuid": "9553BA30-65D9-475F-A049-3108069B07A7",
    "form_completion_date": "2013-4-8",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 567,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 600,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5A64F7E9-3833-4A3C-962B-13EB3E305C69",
    "patient_ID": "TCGA.IS.A3K7",
    "bcr_drug_barcode": "TCGA-IS-A3K7-D38431",
    "bcr_drug_uuid": "155FEE21-5755-4FD7-A972-F506BC2E8FDF",
    "form_completion_date": "2012-12-14",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 126,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 238,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "257DC623-41E1-4FA3-859C-C787DB10BD60",
    "patient_ID": "TCGA.IS.A3KA",
    "bcr_drug_barcode": "TCGA-IS-A3KA-D38432",
    "bcr_drug_uuid": "E795A8CB-0FDB-483F-9060-5AF42AA45570",
    "form_completion_date": "2012-12-14",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 101,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "257DC623-41E1-4FA3-859C-C787DB10BD60",
    "patient_ID": "TCGA.IS.A3KA",
    "bcr_drug_barcode": "TCGA-IS-A3KA-D38433",
    "bcr_drug_uuid": "25FFB536-DE9A-4FA9-AF7A-4BDCA05C740F",
    "form_completion_date": "2012-12-14",
    "pharmaceutical_therapy_drug_name": "MEGACE",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 101,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 187,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0DA5EE6C-D012-4A57-9992-9D74937AAA5F",
    "patient_ID": "TCGA.IW.A3M4",
    "bcr_drug_barcode": "TCGA-IW-A3M4-D33540",
    "bcr_drug_uuid": "CE804F6A-3323-40E7-82AF-6AD406F8E040",
    "form_completion_date": "2012-7-6",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 170,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "0DA5EE6C-D012-4A57-9992-9D74937AAA5F",
    "patient_ID": "TCGA.IW.A3M4",
    "bcr_drug_barcode": "TCGA-IW-A3M4-D33541",
    "bcr_drug_uuid": "D038D104-F4C7-4B09-BB23-BCC122FC0651",
    "form_completion_date": "2013-4-8",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 58,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 170,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "C20682A1-F340-430D-99F9-077FE093ED19",
    "patient_ID": "TCGA.IW.A3M5",
    "bcr_drug_barcode": "TCGA-IW-A3M5-D29480",
    "bcr_drug_uuid": "C3B7FF34-CFCE-44E8-896A-7E346CC160A5",
    "form_completion_date": "2012-3-19",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 154,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 154,
    "drug_cycles": 1,
    "drug_units": "G/M2",
    "drug_tota_dose_units": "MG",
    "drug_dose": 80,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 384000
  },
  {
    "bcr_patient_uuid": "C20682A1-F340-430D-99F9-077FE093ED19",
    "patient_ID": "TCGA.IW.A3M5",
    "bcr_drug_barcode": "TCGA-IW-A3M5-D29481",
    "bcr_drug_uuid": "044E2E4C-BD96-4A2A-A7E3-8456A652757C",
    "form_completion_date": "2012-3-19",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 147,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 170,
    "drug_cycles": 3,
    "drug_units": "G/M2",
    "drug_tota_dose_units": "MG",
    "drug_dose": 675,
    "regimen_number": 1,
    "drug_route": "INTRAVENOUS",
    "therapy_regimen": "ADJUVANT",
    "drug_total_dose": 3240000
  },
  {
    "bcr_patient_uuid": "3EA1CBD8-F74A-4B14-AA49-23D5A47716BA",
    "patient_ID": "TCGA.IW.A3M6",
    "bcr_drug_barcode": "TCGA-IW-A3M6-D32537",
    "bcr_drug_uuid": "40784AB1-C60D-4C0B-B15B-5E5E78E0CED7",
    "form_completion_date": "2012-6-1",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 45,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "3EA1CBD8-F74A-4B14-AA49-23D5A47716BA",
    "patient_ID": "TCGA.IW.A3M6",
    "bcr_drug_barcode": "TCGA-IW-A3M6-D32556",
    "bcr_drug_uuid": "C52F4689-AAC1-4508-A409-237A45D3F4E0",
    "form_completion_date": "2012-6-1",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 24,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 45,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E119DC43-9BA7-43AD-ADD0-1CE8A01E3B06",
    "patient_ID": "TCGA.JV.A5VE",
    "bcr_drug_barcode": "TCGA-JV-A5VE-D45019",
    "bcr_drug_uuid": "C09645C2-FBC3-451E-82F3-A62018A07C2B",
    "form_completion_date": "2013-8-2",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 165,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "E119DC43-9BA7-43AD-ADD0-1CE8A01E3B06",
    "patient_ID": "TCGA.JV.A5VE",
    "bcr_drug_barcode": "TCGA-JV-A5VE-D48464",
    "bcr_drug_uuid": "8D4445D0-D8A8-408F-A082-948A36EFB9F4",
    "form_completion_date": "2013-10-16",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 38,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 165,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CD8637C0-1651-4E8A-9A88-7FB06DC36FF8",
    "patient_ID": "TCGA.JV.A75J",
    "bcr_drug_barcode": "TCGA-JV-A75J-D50126",
    "bcr_drug_uuid": "9CA0FB49-651A-4790-A5FA-CFDD406BA255",
    "form_completion_date": "2013-10-16",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 19,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CD8637C0-1651-4E8A-9A88-7FB06DC36FF8",
    "patient_ID": "TCGA.JV.A75J",
    "bcr_drug_barcode": "TCGA-JV-A75J-D50127",
    "bcr_drug_uuid": "58E8AEA1-2341-4FCD-9118-220362CB66B3",
    "form_completion_date": "2013-10-16",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 19,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F519BE07-434E-4EB2-ACF9-318565B83D50",
    "patient_ID": "TCGA.K1.A3PN",
    "bcr_drug_barcode": "TCGA-K1-A3PN-D33661",
    "bcr_drug_uuid": "8035D68F-26CA-4B63-97FA-8169E03503FD",
    "form_completion_date": "2012-7-12",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 121,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 182,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F519BE07-434E-4EB2-ACF9-318565B83D50",
    "patient_ID": "TCGA.K1.A3PN",
    "bcr_drug_barcode": "TCGA-K1-A3PN-D33662",
    "bcr_drug_uuid": "222926A9-0B3F-4478-8692-11B975685510",
    "form_completion_date": "2012-7-12",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 151,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 182,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9BDC3867-2115-4351-AF5F-A52A2C20AE5D",
    "patient_ID": "TCGA.K1.A42X",
    "bcr_drug_barcode": "TCGA-K1-A42X-D49686",
    "bcr_drug_uuid": "4F0F81AF-2208-40CD-98A9-9B723D5D4255",
    "form_completion_date": "2013-10-15",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2134,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2293,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "9BDC3867-2115-4351-AF5F-A52A2C20AE5D",
    "patient_ID": "TCGA.K1.A42X",
    "bcr_drug_barcode": "TCGA-K1-A42X-D63375",
    "bcr_drug_uuid": "3535D02F-D6F0-4877-8B84-84720DDC0652",
    "form_completion_date": "2014-8-6",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3256,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3417,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "239505CE-F2F1-477E-8AE2-B7065989BA79",
    "patient_ID": "TCGA.K1.A6RT",
    "bcr_drug_barcode": "TCGA-K1-A6RT-D57310",
    "bcr_drug_uuid": "201913C5-B711-4B25-97CC-B4B7692C6449",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 275,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "306C53FB-640D-42AD-889A-ABC5FD3AD778",
    "patient_ID": "TCGA.K1.A6RU",
    "bcr_drug_barcode": "TCGA-K1-A6RU-D57316",
    "bcr_drug_uuid": "0060ABD9-1C93-427A-B7FD-9719013B96EF",
    "form_completion_date": "2014-3-10",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 143,
    "pharmaceutical_tx_ongoing_indicator": false,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F4852819-6C2D-45F7-8479-5E79F143C7B5",
    "patient_ID": "TCGA.KD.A5QS",
    "bcr_drug_barcode": "TCGA-KD-A5QS-D44808",
    "bcr_drug_uuid": "0716E293-6A35-4C13-ADB8-398829AB177F",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 30,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 72,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F4852819-6C2D-45F7-8479-5E79F143C7B5",
    "patient_ID": "TCGA.KD.A5QS",
    "bcr_drug_barcode": "TCGA-KD-A5QS-D45128",
    "bcr_drug_uuid": "8DCE3E46-2D32-4C91-B76E-D00A7E2D393E",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 30,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 72,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F4852819-6C2D-45F7-8479-5E79F143C7B5",
    "patient_ID": "TCGA.KD.A5QS",
    "bcr_drug_barcode": "TCGA-KD-A5QS-D45129",
    "bcr_drug_uuid": "0C02F11C-8C6B-4BCE-B900-32DE2E88571A",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 876,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F4852819-6C2D-45F7-8479-5E79F143C7B5",
    "patient_ID": "TCGA.KD.A5QS",
    "bcr_drug_barcode": "TCGA-KD-A5QS-D45130",
    "bcr_drug_uuid": "FA483FDD-A827-4997-8AD6-8DD333FBF76E",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 366,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 471,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "F4852819-6C2D-45F7-8479-5E79F143C7B5",
    "patient_ID": "TCGA.KD.A5QS",
    "bcr_drug_barcode": "TCGA-KD-A5QS-D45131",
    "bcr_drug_uuid": "7CE55EBA-A4B0-4100-8EF7-ADC0BEDF5FBB",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 499,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 876,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "02B7B0C5-DAD6-4270-B56B-3D04285E8147",
    "patient_ID": "TCGA.KD.A5QU",
    "bcr_drug_barcode": "TCGA-KD-A5QU-D45132",
    "bcr_drug_uuid": "8288E9C0-D448-469C-98D1-C4E56EDF508C",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 93,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 219,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "02B7B0C5-DAD6-4270-B56B-3D04285E8147",
    "patient_ID": "TCGA.KD.A5QU",
    "bcr_drug_barcode": "TCGA-KD-A5QU-D45133",
    "bcr_drug_uuid": "D0BBCEA2-A3A1-4BFC-8FCC-BC8234533FEA",
    "form_completion_date": "2013-7-8",
    "pharmaceutical_therapy_drug_name": "CISPLATIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 93,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 219,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "CA0F032B-A34C-4A92-A403-BC7DC6ECA8E9",
    "patient_ID": "TCGA.KF.A41W",
    "bcr_drug_barcode": "TCGA-KF-A41W-D35696",
    "bcr_drug_uuid": "FF0F21F1-F12A-4C8F-824E-956F8BFA921A",
    "form_completion_date": "2012-10-5",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 61,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 137,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "4482DA24-BD16-4826-A9EA-1078BCB12411",
    "patient_ID": "TCGA.LI.A67I",
    "bcr_drug_barcode": "TCGA-LI-A67I-D68504",
    "bcr_drug_uuid": "6D039CE7-6C7D-41D0-A704-DBE0AF7F5527",
    "form_completion_date": "2014-11-21",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 595,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 670,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "49FD3506-EB64-4ECD-A367-303B1D7A7FC9",
    "patient_ID": "TCGA.MB.A5Y8",
    "bcr_drug_barcode": "TCGA-MB-A5Y8-D43479",
    "bcr_drug_uuid": "FBF07544-F076-44E8-9D00-C5FC90152491",
    "form_completion_date": "2013-5-23",
    "pharmaceutical_therapy_drug_name": "DOXIL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 248,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "49FD3506-EB64-4ECD-A367-303B1D7A7FC9",
    "patient_ID": "TCGA.MB.A5Y8",
    "bcr_drug_barcode": "TCGA-MB-A5Y8-D55673",
    "bcr_drug_uuid": "31545660-81C8-4D5F-9162-A04E2786E58D",
    "form_completion_date": "2014-1-13",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "days_to_drug_start": 248,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "A34CFB9C-44DD-4617-BBD1-28EDC8D527C4",
    "patient_ID": "TCGA.MO.A47P",
    "bcr_drug_barcode": "TCGA-MO-A47P-D58080",
    "bcr_drug_uuid": "B19F3AD3-7DF5-4C25-B2C3-B15239F79B4E",
    "form_completion_date": "2014-3-31",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "days_to_drug_start": 33,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 227,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "5DBD1EED-523E-48CC-B69B-AC905A1116EB",
    "patient_ID": "TCGA.PT.A8TR",
    "bcr_drug_barcode": "TCGA-PT-A8TR-D57928",
    "bcr_drug_uuid": "832BE8DF-1543-4DF9-9F32-B2DD61BE1818",
    "form_completion_date": "2014-3-28",
    "pharmaceutical_therapy_drug_name": "GEMZAR",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 40,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 155,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "5DBD1EED-523E-48CC-B69B-AC905A1116EB",
    "patient_ID": "TCGA.PT.A8TR",
    "bcr_drug_barcode": "TCGA-PT-A8TR-D57933",
    "bcr_drug_uuid": "1768AC31-22FC-444A-87A4-4605B0B4055A",
    "form_completion_date": "2014-3-28",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 40,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 155,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "0F94362D-368F-4570-B8C1-70FC4B1F5E35",
    "patient_ID": "TCGA.QQ.A5VB",
    "bcr_drug_barcode": "TCGA-QQ-A5VB-D58788",
    "bcr_drug_uuid": "25277025-3D72-4CD2-A888-4737B7D7FCFE",
    "form_completion_date": "2014-4-23",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "pharmaceutical_tx_ongoing_indicator": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D59592",
    "bcr_drug_uuid": "F2BCFBAD-4843-4E20-8049-46E1D8B06F32",
    "form_completion_date": "2014-5-15",
    "pharmaceutical_therapy_drug_name": "SULINDAC",
    "pharmaceutical_therapy_type": "ANCILLARY",
    "days_to_drug_start": 529,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1499,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D59593",
    "bcr_drug_uuid": "1150CECC-83B3-43C7-8A26-AC51E065EB89",
    "form_completion_date": "2014-5-15",
    "pharmaceutical_therapy_drug_name": "TAMOXIFEN",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 613,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 1499,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D59597",
    "bcr_drug_uuid": "EDB4D1C8-F8AE-41E4-A32B-E94548D51388",
    "form_completion_date": "2014-5-15",
    "pharmaceutical_therapy_drug_name": "GLEEVEC",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2094,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2780,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D59598",
    "bcr_drug_uuid": "0ADD8E6B-4AE9-4543-9160-95F5527F0824",
    "form_completion_date": "2014-5-15",
    "pharmaceutical_therapy_drug_name": "RALOXIFENE",
    "pharmaceutical_therapy_type": "HORMONE THERAPY",
    "days_to_drug_start": 2807,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 2886,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D59599",
    "bcr_drug_uuid": "4F5C2E4F-8451-4F69-B206-5B11B440F4C0",
    "form_completion_date": "2014-5-15",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 2898,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 3026,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "6E9F74A4-2F41-4B2F-B0E1-39C4D779BD40",
    "patient_ID": "TCGA.QQ.A8VD",
    "bcr_drug_barcode": "TCGA-QQ-A8VD-D66873",
    "bcr_drug_uuid": "AC4361A5-4504-429B-9206-875D3E32B8B6",
    "form_completion_date": "2014-10-24",
    "pharmaceutical_therapy_drug_name": "SORAFENIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 3939,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DE509AA1-6F20-480F-BF9D-D6BC04A7F72C",
    "patient_ID": "TCGA.RN.AAAQ",
    "bcr_drug_barcode": "TCGA-RN-AAAQ-D62295",
    "bcr_drug_uuid": "914CB230-5911-4EFF-8449-46934486E07B",
    "form_completion_date": "2014-7-15",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 40,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 89,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DE509AA1-6F20-480F-BF9D-D6BC04A7F72C",
    "patient_ID": "TCGA.RN.AAAQ",
    "bcr_drug_barcode": "TCGA-RN-AAAQ-D71461",
    "bcr_drug_uuid": "3168AEE1-EA48-426F-A025-4514790AEAB2",
    "form_completion_date": "2015-3-25",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 362,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DE509AA1-6F20-480F-BF9D-D6BC04A7F72C",
    "patient_ID": "TCGA.RN.AAAQ",
    "bcr_drug_barcode": "TCGA-RN-AAAQ-D71464",
    "bcr_drug_uuid": "62EAA7D0-1F8D-4B65-B17F-19688BD2CE10",
    "form_completion_date": "2015-3-25",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 453,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "DE509AA1-6F20-480F-BF9D-D6BC04A7F72C",
    "patient_ID": "TCGA.RN.AAAQ",
    "bcr_drug_barcode": "TCGA-RN-AAAQ-D71465",
    "bcr_drug_uuid": "C055BC14-ABF7-41B5-BEA3-9AD5A3AA889E",
    "form_completion_date": "2015-3-25",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 392,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 453,
    "treatment_best_response": "PARTIAL RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1DB4962A-3CF7-4F36-BD60-46A1B63B6C20",
    "patient_ID": "TCGA.SG.A6Z4",
    "bcr_drug_barcode": "TCGA-SG-A6Z4-D55419",
    "bcr_drug_uuid": "BE112647-9FD8-4277-AAEF-55761E5AD582",
    "form_completion_date": "2014-1-7",
    "clinical_trial_drug_classification": "TH-302",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 228,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A857D684-7195-44F9-BA21-B88020BD9633",
    "patient_ID": "TCGA.SI.A71O",
    "bcr_drug_barcode": "TCGA-SI-A71O-D65180",
    "bcr_drug_uuid": "B8894426-5180-4B83-892A-E743E8C40261",
    "form_completion_date": "2014-10-22",
    "pharmaceutical_therapy_drug_name": "AVASTIN",
    "pharmaceutical_therapy_type": "IMMUNOTHERAPY",
    "days_to_drug_start": 350,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 462,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A857D684-7195-44F9-BA21-B88020BD9633",
    "patient_ID": "TCGA.SI.A71O",
    "bcr_drug_barcode": "TCGA-SI-A71O-D66702",
    "bcr_drug_uuid": "5C7B5E08-DD51-43A2-92FF-07A13956CA5F",
    "form_completion_date": "2014-10-22",
    "pharmaceutical_therapy_drug_name": "EVEROLIMUS",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 350,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 462,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "A857D684-7195-44F9-BA21-B88020BD9633",
    "patient_ID": "TCGA.SI.A71O",
    "bcr_drug_barcode": "TCGA-SI-A71O-D66704",
    "bcr_drug_uuid": "CFD8BEFB-D4A7-47E1-9471-2E41CC24FFE8",
    "form_completion_date": "2014-10-22",
    "pharmaceutical_therapy_drug_name": "TIVOZANIB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 489,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 545,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "2560FB5B-5F49-4D38-8F61-1AB911AED3EB",
    "patient_ID": "TCGA.SI.A71P",
    "bcr_drug_barcode": "TCGA-SI-A71P-D71509",
    "bcr_drug_uuid": "231E3C90-0B94-455D-A491-E214B07C45BD",
    "form_completion_date": "2015-3-26",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 174,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 269,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8372E154-C9C1-4382-8120-7E14DD426367",
    "patient_ID": "TCGA.X2.A95T",
    "bcr_drug_barcode": "TCGA-X2-A95T-D57454",
    "bcr_drug_uuid": "A829DFD3-C239-4447-B661-D28674EEA0F0",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "TAXOTERE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 132,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "8372E154-C9C1-4382-8120-7E14DD426367",
    "patient_ID": "TCGA.X2.A95T",
    "bcr_drug_barcode": "TCGA-X2-A95T-D57459",
    "bcr_drug_uuid": "3AAB17FE-A8DA-4582-97C2-1082FD0E40B1",
    "form_completion_date": "2014-3-11",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 10,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 132,
    "treatment_best_response": "COMPLETE RESPONSE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "1C89DA99-9E89-4726-B196-97EEAB46D504",
    "patient_ID": "TCGA.X6.A7WC",
    "bcr_drug_barcode": "TCGA-X6-A7WC-D67909",
    "bcr_drug_uuid": "8F565E3C-59F7-4AE8-8D04-4C36B8F207C7",
    "form_completion_date": "2014-11-12",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 819,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 854,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "90BC0F31-0EC2-4CEB-AD99-6BE8F8B19180",
    "patient_ID": "TCGA.X6.A8C2",
    "bcr_drug_barcode": "TCGA-X6-A8C2-D68051",
    "bcr_drug_uuid": "43FE82A5-1C14-4C92-B9AE-DABDC6FE1EA2",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "DOXORUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 677,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D57171",
    "bcr_drug_uuid": "F2D26712-31B0-4618-BF2D-F5D501E0B460",
    "form_completion_date": "2014-3-5",
    "clinical_trial_drug_classification": "TH-302",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 156,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D68090",
    "bcr_drug_uuid": "65783E91-8B22-4BF2-BF45-02B7875476AB",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "DOXETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 327,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D68095",
    "bcr_drug_uuid": "38DC0A97-6197-49D7-BCFF-3F7DE14221C4",
    "form_completion_date": "2014-11-13",
    "pharmaceutical_therapy_drug_name": "TRABECTEDIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 511,
    "pharmaceutical_tx_ongoing_indicator": true,
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D69807",
    "bcr_drug_uuid": "BCD131BB-444E-4374-BB31-968326E5E535",
    "form_completion_date": "2015-1-20",
    "pharmaceutical_therapy_drug_name": "BEVACIZUMAB",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 327,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D69808",
    "bcr_drug_uuid": "A184FF52-868D-43A6-A904-04D9471314A9",
    "form_completion_date": "2015-1-20",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 327,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": true
  },
  {
    "bcr_patient_uuid": "B2EE912A-0A57-4D46-BC25-3594028FE387",
    "patient_ID": "TCGA.X6.A8C4",
    "bcr_drug_barcode": "TCGA-X6-A8C4-D69809",
    "bcr_drug_uuid": "8DD34081-2EAC-48D2-A670-6F9E692EA162",
    "form_completion_date": "2015-1-20",
    "pharmaceutical_therapy_drug_name": "VALPROIC ACID",
    "pharmaceutical_therapy_type": "TARGETED MOLECULAR THERAPY",
    "days_to_drug_start": 327,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 504,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "719FA3F6-0194-423D-8A96-3709E8180565",
    "patient_ID": "TCGA.X6.A8C6",
    "bcr_drug_barcode": "TCGA-X6-A8C6-D68289",
    "bcr_drug_uuid": "3A13E060-572E-4755-9847-C96363D98453",
    "form_completion_date": "2014-11-14",
    "pharmaceutical_therapy_drug_name": "DOXIRUBICIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 785,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 840,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "719FA3F6-0194-423D-8A96-3709E8180565",
    "patient_ID": "TCGA.X6.A8C6",
    "bcr_drug_barcode": "TCGA-X6-A8C6-D68303",
    "bcr_drug_uuid": "177312FD-E011-4F3B-87B6-BE59C40B8E29",
    "form_completion_date": "2014-11-14",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 911,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 966,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B0C194CE-8F60-423F-AFCA-7F577813421C",
    "patient_ID": "TCGA.X9.A971",
    "bcr_drug_barcode": "TCGA-X9-A971-D66941",
    "bcr_drug_uuid": "17B6D62D-9809-4C58-8F5D-0ABA8A45A7AA",
    "form_completion_date": "2014-10-29",
    "pharmaceutical_therapy_drug_name": "DOCETAXEL",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 413,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 434,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "B0C194CE-8F60-423F-AFCA-7F577813421C",
    "patient_ID": "TCGA.X9.A971",
    "bcr_drug_barcode": "TCGA-X9-A971-D66942",
    "bcr_drug_uuid": "F5B6039C-1A83-44CA-ACB5-89C6DC008EA9",
    "form_completion_date": "2014-12-19",
    "pharmaceutical_therapy_drug_name": "GEMCITABINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 413,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 434,
    "treatment_best_response": "PROGRESSIVE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "90DB503C-F9C8-4D31-BED4-E3383B69C89B",
    "patient_ID": "TCGA.X9.A973",
    "bcr_drug_barcode": "TCGA-X9-A973-D64503",
    "bcr_drug_uuid": "D6BA0EBE-0350-4C63-8E68-ECDED06A45BC",
    "form_completion_date": "2014-9-4",
    "pharmaceutical_therapy_drug_name": "ADRIAMYCIN",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 323,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "90DB503C-F9C8-4D31-BED4-E3383B69C89B",
    "patient_ID": "TCGA.X9.A973",
    "bcr_drug_barcode": "TCGA-X9-A973-D64513",
    "bcr_drug_uuid": "90E19734-F9E8-4DAA-B97E-1CE1FA545BF7",
    "form_completion_date": "2014-9-4",
    "pharmaceutical_therapy_drug_name": "DACARBAZINE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 323,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  },
  {
    "bcr_patient_uuid": "90DB503C-F9C8-4D31-BED4-E3383B69C89B",
    "patient_ID": "TCGA.X9.A973",
    "bcr_drug_barcode": "TCGA-X9-A973-D64512",
    "bcr_drug_uuid": "730B3E9A-D6B7-4BDD-8F7C-D307DB145B56",
    "form_completion_date": "2014-9-4",
    "pharmaceutical_therapy_drug_name": "IFOSFAMIDE",
    "pharmaceutical_therapy_type": "CHEMOTHERAPY",
    "days_to_drug_start": 323,
    "pharmaceutical_tx_ongoing_indicator": false,
    "days_to_drug_end": 392,
    "treatment_best_response": "STABLE DISEASE",
    "therapy_on_clinical_trial": false
  }
]
